Johnson & Johnson JNJ

Johnson & Johnson (JNJ) stock returned around 52% in the twelve months, against 17% for the S&P 500. A $10,000 holding became about $15,220. Over that period, J&J’s revenue growth accelerated even as the company navigated the anticipated loss of exclusivity and biosimilar erosion for STELARA. If that shift showed up in J&J's calls and filings first, a reader could have spotted it early. So was J&J's run in plain sight before it began.

Key TakeawaysMicrosoft just raised its quarterly dividend 8% to $0. 98, and Johnson & Johnson raised its payout for the 64th straight year in April.

Pfizer's shares cost more than Johnson & Johnson's for each dollar of reported profit, even after factoring in a loss quarter over the past year. Investors usually pay more for growth, yet Pfizer (PFE) had the weakest sales growth of the six companies in its peer group. Are you overpaying for Pfizer stock versus its rivals.

Merck (MRK) stock returned 96% in the past twelve months, against 16.8% for the S&P 500. With the shares 4.0% below their 52-week high, you need a reason Merck can keep growing. In its fiscal Q2 2026 call, management looked past its best-selling drug to newer ones. So what is Merck stock's biggest opportunity from here.

AI-driven discovery, streamlined approvals and partnerships are accelerating drug repurposing, creating opportunities in oncology, rare, neurodegenerative and infectious diseases.Dublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- "Drug Repurposing Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global drug repurposing market was valued at US$29.4 billion in 2024 and is projected to reach US$37.3 billion by 2030, expanding at a compound annual growth ra

Bank of America just raised price targets on two pharma giants facing patent cliffs, but its conviction level differs sharply between them, and the valuation gap may explain which one belongs in a long-term portfolio right now.

Johnson & Johnson (NYSE:JNJ) reported new long term IMAAVY data in generalized myasthenia gravis, including adolescent outcomes. The company said adolescents with gMG on IMAAVY showed sustained disease control and reduced reliance on corticosteroids, with no new safety signals. Survey findings from healthcare professionals indicated IMAAVY may address unmet needs for more consistent symptom management in gMG treatment. The new IMAAVY findings in adolescent gMG sit alongside broader shifts...

Look at the breakdown of Intuitive Surgical's revenue streams—Instruments and Accessories alone generate roughly 60% of the top line on a per-procedure basis. That tight link between surgery volume and cash flow explains why investors reacted so sharply when Intuitive noted in its fiscal Q2 2026 call that U.S. procedure growth had slowed. With recurring earnings visibility clouded, how much downside risk is the market actually pricing in.

Note: The stock trades in this article come from Rallies Arena, an account on X (@ralliesarena) that runs the Rallies AI Stock Market Arena, an experiment where AI models manage stock portfolios and try to beat the S&P 500. Rallies Arena recently allocated funds to Muse AI, Meta Platform’s new AI agent that is making […]

You may own Eli Lilly (LLY), a drugmaker worth about $1.05 trillion, beside funds that already track the S&P 500. A single stock can become a big part of your money, so its daily moves matter for all of it. Is Eli Lilly stock a good fit for the risk you already carry.

Johnson & Johnson (NYSE:JNJ)'s oral psoriasis drug Icotyde could reach $4.5 billion in peak sales, up from a previous $2.4 billion estimate, Bank of America said as it raised its price target on the company to $278 from $263. The broker now values estimated 2027 earnings excluding...

Eli Lilly (LLY) raised its revenue forecast for 2026 on August 5, when it reported second-quarter results. Since the close before that release, Eli Lilly stock has gained 6.3%, while the S&P 500 fell 0.7%. The raise was modest and came with a lower earnings forecast, which is why the price chart is worth a look. So does Eli Lilly's price chart agree with management.

Recently published Retinitis Pigmentosa Market Insights report includes a comprehensive understanding of current treatment practices, retinitis pigmentosa emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].